Skip to content

68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy

Upper Digestive Tract Cancer

Upper gastrointestinal (GI) cancers are a major health problem in Canada. At the metastatic stage, options are limited (usually chemotherapy, immunotherapy, personalized therapies under research protocols). These options are not applicable to all patients and may have significant toxicities. Endoradiotherapy (ERT) using a radioisotope coupled with a localization vector specifically targeting tumor cells to deliver a localized dose of radiation therapy is a promising avenue as it can treat disseminated neoplastic disease in a specific manner sparing healthy tissue with minimal side effects. The main goal of this study is to confirm that patients with upper GI cancer would be eligible for ERT (177Lu-PSMA treatment by using 68Ga-PSMA PET/CT assessment).

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Age 18 years and older
* Active cancer of the type adenocarcinoma (of the esophagus, of the stomach, of the bile ducts, or of the pancreas) documented by a CT scan performed within the last 8 weeks at the time of recruitment.

* An active cancer is defined as at least one lesion identified as stable or progressive neoplastic on CT imaging.
* A lesion treated with local therapy (e.g., external radiotherapy, cryoablation, radiofrequency ablation, resection) is not counted for inclusion criteria if this is done between the CT scan and the 68Ga-PSMA PET imaging. A lesion treated prior to the last CT scan may be considered eligible if progression is documented at the last CT scan.
* Able to provide free and informed consent.
* Feasibility to perform 68Ga-PSMA PET within 2 months of the CT scan that was used for inclusion.

Exclusion Criteria:

* Other active cancer (non-metastatic non-melanoma skin cancer excluded). Cancer in remission for at least 3 years will not be considered active.
* ECOG \> 3.
* Pregnant woman.
* Unable to follow study rules.

Study Location

CIUSSS de l'Estrie- CHUS Hospital
CIUSSS de l'Estrie- CHUS Hospital
Sherbrooke, Quebec
Canada

Contact Study Team

Primary Contact

Etienne Croteau, PhD

[email protected]
819 346-1110
Study Sponsored By
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Participants Required
More Information
Study ID: NCT05214820